济南龟头流出来的液体(济南专业治疗男科的医院是哪家) (今日更新中)

The Food and Drug Administration has approved remdesivir as a treatment for the coronavirus.The move comes less than a week after the World Health Organization published results of a large study that suggested remdesivir did not help hospitalized COVID-19 patients.A previous study by the U.S. National Institutes of Health found the antiviral drug shortened recovery time by five days, on average. That led to the drug getting emergency use approval in the U.S, as well as many other countries.The FDA’s decision on Thursday formally approves remdesivir as a treatment option, and makes it the first fully-approved treatment in the U.S.None of the studies have found the drug can improve survival rates.Remdesivir is one of the treatments President Donald Trump received when he contracted COVID-19 earlier this month. It is usually given over five days and works by helping to stop the replication of COVID-19 in the body. 932

The Department of Homeland Security formally requested that the Pentagon extend the deployment of active-duty troops on the southern border Friday, potentially extending their deployment 45 days beyond the original deadline of December 15."Given the ongoing threat at our Southern border -- today the Department of Homeland Security submitted a request for assistance to the Department of Defense to extend its support through January 31, 2019," Department of Homeland Security spokeswoman Katie Waldman told CNN in a statement."This request refines support to ensure it remains aligned with the current situation, the nature of the mission, and (Customs and Border Protection) operational requirements," she added.The Pentagon confirmed receipt of the request but said Secretary of Defense James Mattis had yet to sign off on it:"We have received the Request for Assistance from the Department of Homeland Security, it is with the Secretary (of Defense) for consideration."There are currently some 5,600 troops at the border, divided among Texas, California and Arizona.President Donald Trump sent the troops after spending the weeks leading up to the midterm elections decrying a procession of migrants that was still thousands of miles from the US border. Last week, Trump granted the troops new powers to aid in "crowd control, temporary detention and cursory search" while protecting Customs and Border Protection personnel from the migrants, should they engage in violence.Defense officials have suggested that some of the troops, primarily engineers involved in enhancing infrastructure at points of entry, could be drawn down in the relative near term as those tasks are completed.Two officials tell CNN that the number of trumps assigned to the mission is likely to drop to 4,000 as a result.Other functions, including helicopter support to help move Customs and Border Protection personnel to different areas along the border, are likely to continue.The deployment's extension means the Pentagon's initial cost estimate of million for the border deployment is likely to increase as that estimate was based on the mission ending on December 15. 2175

The city of Philadelphia has settled with two black men arrested at a Starbucks in the city. Rashon Nelson and Donte Robinson settled for apiece while the city committed 0,000 for young entrepreneurs, according to the New York Daily News. The two men were arrested after sitting down at the Starbucks without ordering anything. Starbucks also reached a settlement with the two men, the company said in a statement. The deal includes a financial settlement. "I want to thank Donte and Rashon for their willingness to reconcile," Starbucks CEO Kevin Johnson said in the statement. "I welcome the opportunity to begin a relationship with them to share learnings and experiences. And Starbucks will continue to take actions that stem from this incident to repair and reaffirm our values and vision for the kind of company we want to be."   889

The Food and Drug Administration on Wednesday authorized the first rapid coronavirus test that doesn’t need any special computer equipment to get results.The 15-minute test from Abbott Laboratories will sell for , giving it a competitive edge over similar tests that need to be popped into a small machine. The size of a credit card, the self-contained test is based on the same technology used to test for the flu, strep throat and other infections.It’s the latest cheaper, simpler test to hit the U.S. market, providing new options to expand testing as schools and businesses struggle to reopen and flu season approaches. The FDA also recently greenlighted a saliva test from Yale University that bypasses some of the supplies that have led to testing bottlenecks.Both tests have limitations and neither can be done at home. Several companies are developing rapid, at-home tests, but none have yet won approval. Abbott’s new test still requires a nasal swab by a health worker, like most older coronavirus tests. The Yale saliva test eliminates the need for a swab, but can only be run at high-grade laboratories.And in general, rapid tests like Abbott’s are less accurate than lab-developed tests. The FDA said in a statement announcing the decision that negative results with Abbott’s test may need to be confirmed with a lab test in some cases. The agency granted Abbott’s test an emergency use authorization late Wednesday for patients with suspected COVID-19.The two additions should help expand the number of available tests. The U.S. is now testing about 690,000 people per day, down from a peak of 850,000 daily tests late last month. Many public health experts believe the country will soon need to test vastly more people to find those who are infected, isolate them and contain the virus.The FDA noted that Abbott’s test could be used in a doctor’s office, emergency room or some schools. “Given the simple nature of this test, it is likely that these tests could be made broadly available,” the FDA said.Since the start of the pandemic, nasal swab tests that are sent to a lab have been the standard for COVID-19 screening. While considered highly accurate, the tests rely on expensive, specialized machines and chemicals. Shortages of those supplies have led to repeated delays in reporting results, especially during a spike in cases last month.Government and health experts view rapid tests that can be run outside the laboratory system as key to boosting capacity.“Those screening tests are what we need in schools, workplaces and nursing homes in order to catch asymptomatic spreaders,” said Dr. Jonathan Quick of the Rockefeller Foundation, in an interview earlier this month. The nonprofit group has called for the U.S. to conduct about 4 millions per day by October, mostly rapid, point-of-care tests.Abbott’s BinaxNOW is the fourth rapid test that detects COVID-19 antigens, proteins found on the surface of the coronavirus, rather than the virus itself. It’s considered a faster, though sometimes less precise, screening method. The other tests need to be inserted into a small machine.Inside the Abbott test is a specially coated strip that interacts with COVID-19 antigens. The patient’s nasal swab is inserted into the card and a few drops of a chemical solution are added. Markings appear on the card to indicate whether the sample is positive or negative — much like a pregnancy test.Two other makers of antigen tests — Quidel and Becton Dickinson have said they haven’t been able to meet demand for the tests. A third, LumiraDx, plans to begin shipping its recently approved antigen tests by the end of this month. Abbott expects to begin shipping tests in September, reaching 50 million tests a month in October.The influx of antigen tests will go a long way toward meeting the Trump administration’s projection that 90 million COVID-19 tests a month will be available by September if needed. But U.S. “testing czar” Adm. Brett Giroir has stressed that the U.S. can contain the outbreak with far fewer tests.“That’s the capacity ... we do not need that many tests to safely and sensibly reopen,” Giroir told reporters on a recent call. He pointed to several key indicators that have been falling, including new infections and hospitalizations, even as testing has slowed.Earlier this month, the FDA authorized Yale’s saliva-based test, which is expected to cut the time and cost compared with similar tests. It’s the fifth COVID-19 saliva tests OK’d by regulators. All require lab processing.Developed by Yale’s School of Public Health, SalivaDirect can use any sterile container to collect a sample, not the special tube needed with earlier tests, and requires less chemicals. Outside experts welcomed the new approach but noted its limitations.“It’s not a rapid test, it’s a laboratory-based test that will still be prone to the same massive delays as any other test,” said Dr. Michael Mina of Harvard University.___Follow Matthew Perrone on Twitter: @ AP_FDAwriter.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5201

The Centers for Disease Control and Prevention announced in a report on Tuesday that the number of people infected by mosquitoes, ticks and fleas has tripled from 2004 through 2016. And as the number of infections increase, the CDC says the US is not prepared to reverse the trend. According to CDC figures, 27,388 cases of disease from mosquitoes, ticks and fleas were reported in 2004. In 2016, that number had increased to 96,075. “Zika, West Nile, Lyme, and chikungunya—a growing list of diseases caused by the bite of an infected mosquito, tick, or flea—have confronted the U.S. in recent years, making a lot of people sick. And we don’t know what will threaten Americans next,” said CDC Director Robert R. Redfield, M.D. “Our Nation’s first lines of defense are state and local health departments and vector control organizations, and we must continue to enhance our investment in their ability to fight against these diseases.”The CDC said that the most common mosquito-borne viruses were West Nile, dengue and Zika.Here are others facts the CDC provided:  1111

来源：资阳报